



Toxicological Profile for Chlorodibenzofurans (CDFs)

Draft for Public Comment

January 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health-related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
January 2022	Draft for public comment toxicological profile released
May 1994	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Hana R. Pohl, M.D., Ph.D. (Lead)
Breanna Alman, M.P.H.
Franco Scinicariello, M.D., M.P.H.

Lisa Ingerman, Ph.D., D.A.B.T.
Mario Citra, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Center for Public Health and Assessment; EPA, Office of Water.

PEER REVIEWERS

1. Michael D. Collins, Ph.D., M.S.P.H., M.S., Professor; UCLA Fielding School of Public Health; Los Angeles, California
2. Charles J. Everett, Ph.D.; U.S. Department of Veterans Affairs; Ralph H. Johnson VA Medical Center; Charleston, South Carolina
3. Eric J. Reiner; University of Toronto; Toronto, Ontario, Canada

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLs)	10
CHAPTER 2. HEALTH EFFECTS	16
2.1 INTRODUCTION	16
2.2 DEATH	50
2.3 BODY WEIGHT	51
2.4 RESPIRATORY	54
2.5 CARDIOVASCULAR	55
2.6 GASTROINTESTINAL	57
2.7 HEMATOLOGICAL	58
2.8 MUSCULOSKELETAL	59
2.9 HEPATIC	60
2.10 RENAL	64
2.11 DERMAL	65
2.12 OCULAR	67
2.13 ENDOCRINE	68
2.14 IMMUNOLOGICAL	71
2.15 NEUROLOGICAL	75
2.16 REPRODUCTIVE	77
2.17 DEVELOPMENTAL	83
2.18 OTHER NONCANCER	105
2.19 CANCER	107
2.20 MECHANISM OF ACTION	111
2.21 GENOTOXICITY	113
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	116
3.1 TOXICOKINETICS	116
3.1.1 Absorption	116
3.1.2 Distribution	119
3.1.3 Metabolism	125
3.1.4 Excretion	127
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	132
3.1.6 Animal-to-Human Extrapolations	134
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	134
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	135

3.3.1	Biomarkers of Exposure.....	136
3.3.2	Biomarkers of Effect.....	137
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	138
CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION.....	140
4.1	CHEMICAL IDENTITY.....	140
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	140
CHAPTER 5.	POTENTIAL FOR HUMAN EXPOSURE.....	148
5.1	OVERVIEW.....	148
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	151
5.2.1	Production.....	151
5.2.2	Import/Export.....	154
5.2.3	Use.....	154
5.2.4	Disposal.....	154
5.3	RELEASES TO THE ENVIRONMENT.....	156
5.3.1	Air.....	165
5.3.2	Water.....	165
5.3.3	Soil.....	166
5.4	ENVIRONMENTAL FATE.....	167
5.4.1	Transport and Partitioning.....	167
5.4.2	Transformation and Degradation.....	172
5.5	LEVELS IN THE ENVIRONMENT.....	174
5.5.1	Air.....	177
5.5.2	Water.....	185
5.5.3	Sediment and Soil.....	186
5.5.4	Other Media.....	188
5.6	GENERAL POPULATION EXPOSURE.....	195
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	207
CHAPTER 6.	ADEQUACY OF THE DATABASE.....	209
6.1	INFORMATION ON HEALTH EFFECTS.....	209
6.2	IDENTIFICATION OF DATA NEEDS.....	211
6.3	ONGOING STUDIES.....	218
CHAPTER 7.	REGULATIONS AND GUIDELINES.....	219
CHAPTER 8.	REFERENCES.....	221
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR CDFS.....	B-1
APPENDIX C.	USER'S GUIDE.....	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	D-1
APPENDIX E.	GLOSSARY.....	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	F-1

LIST OF FIGURES

1-1. Basic Chemical Structure of Chlorodibenzofurans (CDFs), Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs), and Polychlorinated Biphenyls (PCBs).....	2
1-2. Health Effects Found in Animals Following Oral Exposure to 2,3,7,8-Tetrachloro-dibenzofuran	5
1-3. Health Effects Found in Animals Following Oral Exposure to 1,2,3,7,8-Pentachloro-dibenzofuran	6
1-4. Health Effects Found in Animals Following Oral Exposure to 2,3,4,7,8-Pentachloro-dibenzofuran	7
1-5. Health Effects Found in Animals Following Oral Exposure to 1,2,3,6,7,8-Hexachloro-dibenzofuran	8
1-6. Summary of Sensitive Targets of 1,2,3,7,8-Pentachlorodibenzofuran – Oral	11
1-7. Summary of Sensitive Targets of 2,3,4,7,8-Pentachlorodibenzofuran – Oral	12
1-8. Summary of Sensitive Targets of 1,2,3,6,7,8-Hexachlorodibenzofuran – Oral.....	13
2-1. Overview of the Number of Studies Examining Chlorodibenzofurans (CDFs) Health Effects	23
2-2. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Oral.....	40
5-1. Number of NPL Sites with Chlorodibenzofuran (CDF) Contamination	148
6-1. Summary of Existing Health Effects Studies on Chlorodibenzofurans (CDFs) By Route and Endpoint	210

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,2,3,7,8-Pentachlorodibenzofuran.....	14
1-2. Minimal Risk Levels (MRLs) for 2,3,4,7,8-Pentachlorodibenzofuran.....	14
1-3. Minimal Risk Levels (MRLs) for 1,2,3,6,7,8-Hexachlorodibenzofuran	15
2-1. Summary of World Health Organization (WHO) 1998 and 2005 Toxicity Equivalency Factors (TEFs).....	19
2-2. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Oral.....	24
2-3. Levels of Significant Exposure to Chlorodibenzofurans (CDFs) – Dermal	48
2-4. Results of Epidemiological Studies Evaluating Exposure to CDFs and Body Weight Effects.....	52
2-5. Results of Epidemiological Studies Evaluating Exposure to CDFs and Cardiovascular Effects	55
2-6. Results of Epidemiological Studies Evaluating Exposure to CDFs and Dermal Effects	66
2-7. Results of Epidemiological Studies Evaluating Exposure to CDFs and Reproductive Effects.....	77
2-8. Results of Epidemiological Studies Evaluating Exposure to CDFs and Developmental Effects.....	84
2-9. Results of Epidemiological Studies Evaluating Exposure to CDFs and Other Noncancer Effects.....	105
2-10. Results of Epidemiological Studies Evaluating Exposure to CDFs and Cancer Effects	108
2-11. Genotoxicity of Chlorodibenzofurans (CDFs) <i>In Vitro</i>	114
3-1. Half-Times of Various CDF Congeners in Hepatic and Adipose Tissues of Marmoset Monkeys Subcutaneously Administered a Single Dose of a CDD/CDF Mixture	121
3-2. Estimated Blood Elimination Half-Lives for Chlorodibenzofuran (CDF) Congeners in Humans.....	128
4-1. Chemical Identity of Chlorodibenzofurans (CDFs).....	141
4-2. Physical and Chemical Properties of Chlorodibenzofurans (CDFs)	143
5-1. Facilities that Produce, Process, or Use Dioxin-like Compounds	151
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Dioxin-like Compounds.....	157
5-3. Levels of Chlorodibenzofurans (CDFs) in Commercial Chlorinated Phenols ($\mu\text{g/g}$)	162
5-4. Levels of Chlorodibenzofurans (CDFs) in Commercial Polychlorinated Biphenyls (PCBs) ($\mu\text{g/g}$)	163
5-5. Estimated BCFs and BAFs for Chlorodibenzofurans (CDFs) in Aquatic Organisms.....	170

5-6. Lowest Limit of Detection Based on Standards	174
5-7. Summary of Environmental Levels of Chlorodibenzofurans (CDFs)	174
5-8. Chlorodibenzofuran (CDF) Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	175
5-9. Congener-specific Monitoring Data from the NDAMN 1998–2004.....	177
5-10. Concentrations of Chlorodibenzofurans (CDFs) in Ambient Indoor and Outdoor Air in North America and Oceans.....	179
5-11. Levels of Chlorodibenzofurans (CDFs) in Fish and Other Aquatic Organisms	189
5-12. Chlorodibenzofuran (CDF) Levels (pg/g lipid) in the U.S. Population 1999–2004.....	196
5-13. Chlorodibenzofuran (CDF) Levels (pg/g lipid) in the U.S. Population 2005-2010	197
5-14. Levels of Chlorodibenzofurans (CDFs) in Human Adipose Tissue	204
5-15. Levels of Chlorodibenzofurans (CDFs) in Human Milk	205
5-16. Mean Levels of Chlorodibenzofurans (CDFs) in Human Whole Blood (ppt lipid) from Various Countries	207
7-1. Regulations and Guidelines Applicable to Chlorodibenzofurans (CDFs).....	219